Rhythm Biosciences Appoints CEO; Shares Down 3%
Rhythm Biosciences (ASX:RHY) appointed David Atkins as chief executive, effective May 13. Atkins has experience across a broad range of life sciences and healthcare disciplines, according to a Wednesd
Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3%
Rhythm Biosciences (ASX:RHY) received AU$2.5 million under its nonrenounceable rights issue. Shares and options under the rights issue will be allotted March 21 and start trading March 22, according t
Rhythm Biosciences Seeks to Raise AU$6.6 Million Via Rights Offer; Shares Fall 29%
Rhythm Biosciences (ASX:RHY) is undertaking a 3-for-10 nonrenounceable rights issue at AU$0.10 apiece to raise about AU$6.6 million. Proceeds will be used to transition the current ColoSTAT test to th
Companies Like Rhythm Biosciences (ASX:RHY) Could Be Quite Risky
Rhythm Biosciences Identifies Lung Cancer Biomarkers From Blood Samples; Shares Fall 6%
Rhythm Biosciences (ASX:RHY) identified potential lung cancer biomarkers following a study conducted by bioanalytical partner the Baker Institute, the diagnostic firm said on Friday. The study analyze
Rhythm Biosciences Receives First Tranche of R&D Tax Rebate
Medical diagnostics company Rhythm Biosciences (ASX:RHY) received the first tranche of AU$1.7 million in research and development tax incentive. The second tranche of the tax rebate is expected in 202
Rhythm Biosciences' Breast Cancer Diagnostic Test Shows Positive Results
Rhythm Biosciences (ASX:RHY), in an update on its cancer diagnostics technology platform expansion program, said it has, along with Agilex Biolabs, identified four biomarkers that "exhibit a strong co
Rhythm Biosciences Joins Forces to Automate Cancer Test Kit
Rhythm Biosciences (ASX:RHY) signed a deal with specialist medical laboratory Nutripath to automate the processing of the ColoSTAT colorectal cancer diagnostic kit. Automating the test will allow for
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Stocks of the Hour: Magnis Energy, QX Res, Rhythm Biosciences, Wildcat Res
Magnis Energy Technologies (ASX:MNS; OTCQX: MNSEF; FSE:U1P) has announced that their lithium ion cell manufacturer iM3NY has entered into a JV Agreement with OSM. iM3NY CEO commented: "This partnershi
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
No Data